| 31R Stock | | | EUR 0.01 0.01 1,800% |
CFO
Carmelo Marrelli is Chief Financial Officer, Secretary of Revive Therapeutics since 2015.
| Tenure | 10 years |
| Phone | 888 901 0036 |
| Web | https://www.revivethera.com |
Revive Therapeutics Management Efficiency
The company has return on total asset
(ROA) of
(0.4252) % which means that it has lost $0.4252 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity
(ROE) of
(0.8286) %, meaning that it generated substantial loss on money invested by shareholders. Revive Therapeutics' management efficiency ratios could be used to measure how well Revive Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.
Revive Therapeutics has accumulated 60
K in total debt with debt to equity ratio
(D/E) of 0.01, which may suggest the company is not taking enough advantage from borrowing. Revive Therapeutics has a current ratio of 31.32, suggesting that it is
liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Revive Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Revive Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Revive Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Revive to invest in growth at high rates of return. When we think about Revive Therapeutics' use of debt, we should always consider it together with cash and equity.
Revive Therapeutics Ltd., a life sciences company, focuses on the research and development of therapeutics for rare disorders and infectious diseases. The company was incorporated in 2012 and is headquartered in Toronto, Canada. REVIVE THERAPEUTICS operates under Drug ManufacturersSpecialty Generic classification in Germany and is traded on Frankfurt Stock Exchange. Revive Therapeutics (31R) is traded on Frankfurt Exchange in Germany and employs 15 people.
Management Performance
Revive Therapeutics Leadership Team
Elected by the shareholders, the Revive Therapeutics' board of directors comprises two types of representatives: Revive Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Revive. The board's role is to monitor Revive Therapeutics' management team and ensure that shareholders' interests are well served. Revive Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Revive Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Robbie Grossman, Director | |
| Christian Scovenna, Director | |
| Carmelo Marrelli, Chief Financial Officer, Secretary | |
| Michael Frank, Chairman of the Board, Chief Executive Officer | |
| Derrick Welsh, COO Pharma | |
| Anton Konovalov, Director | |
| Reiza Rayman, Director | |
| Andrew Lindzon, Director | |
| Onesmo Mpanju, Chief Consultant | |
| Scott Johnson, Director | |
| ACIS BComm, Chief Officer | |
| McKee MD, Chief Consultant | |
Revive Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Revive Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Currently Active Assets on Macroaxis
Other Information on Investing in Revive Stock
Revive Therapeutics financial ratios help investors to determine whether Revive Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Revive with respect to the benefits of owning Revive Therapeutics security.